Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 20,644	$ 28,685
Accounts receivable and other receivables, net of allowance for doubtful accounts of $3 and $76 as of December 31, 2022 and 2021, respectively	1,287	1,370
Inventories, net — current	2,571	4,433
Assets held for sale	87	0
Prepaid expenses and other current assets	809	900
Total current assets	25,398	35,388
Property and equipment, net	704	2,291
Right of use assets	1,848	3,081
Inventories, net — noncurrent	767	2,494
Intangible assets, net	40	484
Other noncurrent assets	165	180
Total assets	28,922	43,918
Current liabilities:
Accounts payable and accrued expenses	2,881	3,638
Amounts due to related parties	48	64
Operating lease liability - current	1,010	1,074
Other current liabilities	270	264
Total current liabilities	4,209	5,040
Operating lease liability - noncurrent	1,007	2,220
Common stock warrant and option liabilities	806	3,392
Other noncurrent liabilities	2,000	2,070
Total liabilities	8,022	12,722
Commitments and contingencies (Note 16)
Stockholders’ equity:
Common stock, $0.001 par value-150,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 616,079 and 554,609 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively.	65	63
Additional paid-in capital	278,827	257,515
Accumulated deficit	(257,859)	(226,485)
Total Arcadia Biosciences stockholders’ equity	21,033	31,093
Non-controlling interest	(133)	103
Total stockholders' equity	20,900	31,196
Total liabilities and stockholders’ equity	$ 28,922	$ 43,918